Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States

References

• National Cancer Institute: US Institutes of Health. Myelodysplastic Syndromes Treatment (PDQ®): General Information about myelodysplastic syndromes. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/allpages/ [Accessed August 16, 2010]
   Google Scholar
• Molassiotis A, Saunders MP, Valle J, A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008;16:201-208
   PubMed Web of Science ®Google Scholar
• Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503
   PubMed Web of Science ®Google Scholar
• Berger AM, Clark-Snow, RA. Nausea and vomiting. In: De Vita VT, Hellman S, Rosenberg RA, eds. Cancer: Principles and Practice in Oncology, 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:2869-2880
   Google Scholar
• Haiderali A, Menditto L, Good M, et al. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer 2010. [Epub ahead of print]
   Google Scholar
• Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24:2932-2947
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Roila F, Tonato M, Herstedt J; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. MASCC/ESMO Antiemetic Guideline 2010. Available at: www.mascc.org [Accessed August 16, 2010]
   Google Scholar
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™: Antiemesis. Version 2.2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Accessed August 16, 2010]
   Google Scholar
• Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 2010. doi: 10.1007/s00520-009-0797-x
   Google Scholar
• Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-536
   PubMed Web of Science ®Google Scholar
• Annemans L, Strens D, Lox E, et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 2008;16:905-915
   PubMed Web of Science ®Google Scholar
• Ballatori E, Roila F, Ruggeri B, et al. The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer 2007;15:31-38
   PubMed Web of Science ®Google Scholar
• Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007;110:678-685
   PubMed Web of Science ®Google Scholar
• Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2005;2:181-187
   PubMedGoogle Scholar
• Stewart DJ, Dahrouge S, Coyle D, et al. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 1999;17:344-351
   Google Scholar
• Weiner MG, Livshits A, Carozzoni C, et al. Derivation of malignancy status from ICD-9 codes. American Medical Informatics Association 2003 Symposium Proceedings: 1050
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
   PubMedGoogle Scholar
• Holdsworth MT. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005;39:1903-10
   Google Scholar
• Italian Group for Antiemetic Research. Transferability of clinical practice of the clinical results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 1998;9:759-765
   PubMed Web of Science ®Google Scholar
• Aapro M. Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin 2005;21:885-897
   PubMed Web of Science ®Google Scholar
• Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007;5:374-380
   PubMedGoogle Scholar
• Ghafoor A, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003;53:342-355
   PubMed Web of Science ®Google Scholar
• Kris M. Why do we need another antiemetic? Just ask. J Clin Oncol 2003;21:4077-4080
   PubMed Web of Science ®Google Scholar
• Feinberg B, Gilmore J, Haislip S, et al. Likelihood of a subsequent chemotherapy induced nausea and vomiting (CINV) event in patients receiving low emetogenic chemotherapy (LEC). Presented at the 2010 International Cancer Education Conference, October 25-27, 2010; San Diego, CA
   Google Scholar
• Feinberg B, Gilmore J, Haislip S, et al. Likelihood of a subsequent chemotherapy induced nausea and vomiting (CINV) event in patients receiving moderately or highly emetogenic chemotherapy (MEC/HEC).Presented at the 2010 ISPOR European Congress, November 6-9, 2010; Prague, Czech Republic
   Google Scholar
• Petrella T, Clemons M, Joy A, et al. Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool. J Support Oncol 2009;7:W9-16
   PubMedGoogle Scholar
• Peters N, Armstrong K. Racial differences in prostate cancer treatment outcomes: a systematic review. Cancer Nurs 2005;28:108-118
   PubMed Web of Science ®Google Scholar
• Marcella S, Miller JE. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol 2001;54:359-366
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Kalemkerian GP. Racial differences in lung cancer. Cancer Metastasis Rev 2003;22:39-46
   Google Scholar
• Zofran® Injection (ondansetron hydrochloride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2010
   Google Scholar
• Anzemet® Tablets (dolasetron mesylate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2009
   Google Scholar
• Kytril® Injection (granisetron hydrochloride) [prescribing information]. Nutley, NJ: Roche Laboratories Inc; October 2009
   Google Scholar
• Aloxi® Injection (palonosetron hydrochloride) [prescribing information]. Bloomington, MN: MGI Pharma Inc; August 2007
   Google Scholar
• Yeh YC, McDonnell A, Klinger E, et al. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 2010. doi: 10.1177/1078155210366491
   Google Scholar
• Feinberg BA, Gilmore J, Haislip S, et al. Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting. Commun Oncol 2009;6:62-67
   Google Scholar
• Vanscoy GJ, Fortner B, Smith R, et al. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Community Oncol 2005;2:127-132
   Google Scholar